AI주식인사이트AI Stock Insight
C

선바이오

067370KOSDAQ의약품 제조업

45.5 / 100

Reference Date: 2026-04-13

Financial Score16.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Rose 6.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SunBio focuses on developing and selling PEG-filgrastim (a neutropenia treatment), MucoPEG (a xerostomia treatment), and artificial blood SBX, along with producing and selling PEG derivatives. PEG-filgrastim is under U.S. approval proceedings, while MucoPEG faces delays in U.S. market entry due to patent issues. The company is also advancing research on solid electrolytes for lithium-ion batteries and aims to enhance competitiveness through a new factory in Incheon.

Number of Employees

29people

Average Salary

51.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
23.28Industry Average 14.801.5Point

1.6x industry avg (risky)

PBR
2.25Industry Average 1.040.0Point

2.2x industry avg (risky)

ROE
9.99Industry Average 4.427.0Point

2.3x industry avg (excellent)

Debt Ratio
35.91Industry Average 11.980.0Point

3.0x industry avg (risky)

Trend 2023~20257.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲467.1% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 9.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 5,330Won52-week high 8,00052-week low 4,945
1-month return4.0Point

1m +6.92% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
  • Neutral정기주주총회결과2026-03-24
  • Neutral사업보고서 (2025.12)2026-03-16
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-16